Consequently, our analysis cannot differentiate between patients with sustained, adherent DMD therapy versus those with sporadic or poor adherence, both classified as “exposed.” Additionally, the analysis does not account for DMD-switching patterns, which are common in MS management and may have independent effects on cognitive outcomes. Here, DMD is linked to myeloid sarcoma.